In January 2024, TaurusTrio AR TAVR System  successfully completed patient enrollment in its multicenter pivotal clinical trial. Since July 2023, the study has exceeded expectations by enrolling 116 patients with aortic regurgitation in 6 months, leading the industry in development progress. TaurusTrio is a transfemoral aortic regurgitation indicated TAVR product exclusively licensed-in by Peijia Medical from JenaValve Technology, Inc. and is now commercially available in Hong Kong, China.